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Abstract
Introduction: The OCT4 transcription factor is involved in many cellular processes, including development,
reprogramming, maintaining pluripotency and differentiation. Synthetic OCT4 mRNA was recently used (in
conjunction with other reprogramming factors) to generate human induced pluripotent stem cells. Here, we
discovered that BAY 11-7082 (BAY11), at least partially through an NF-B-inhibition based mechanism, could
significantly increase the expression of OCT4 following transfection of synthetic mRNA (synRNA) into adult human
skin cells.
Methods: We tested various chemical and molecular small molecules on their ability to suppress the innate
immune response seen upon synthetic mRNA transfection. Three molecules - B18R, BX795, and BAY11 - were used
in immunocytochemical and proliferation-based assays. We also utilized global transcriptional meta-analysis
coupled with quantitative PCR to identify relative gene expression downstream of OCT4.
Results: We found that human skin cells cultured in the presence of BAY11 resulted in reproducible increased
expression of OCT4 that did not inhibit normal cell proliferation. The increased levels of OCT4 resulted in
significantly increased expression of genes downstream of OCT4, including the previously identified SPP1, DUSP4
and GADD45G, suggesting the expressed OCT4 was functional. We also discovered a novel OCT4 putative
downstream target gene SLC16A9 which demonstrated significantly increased expression following elevation of
OCT4 levels.
Conclusions: For the first time we have shown that small molecule-based stabilization of synthetic mRNA
expression can be achieved with use of BAY11. This small molecule-based inhibition of innate immune responses
and subsequent robust expression of transfected synthetic mRNAs may have multiple applications for future cell-
based research and therapeutics.
Introduction
Early embryonic development creates an inner cell mass
in the developing embryo that, after delamination into
the epiblast, initially lends itself exclusively to pluripo-
tent stem cells capable of differentiating into any of over
200 cell types of the human body. The gene expression
and transcriptional network that are expressed and
regulated are well characterized [1-4]. One of the key
pluripotency factors, OCT4, a Pou class 5 homeobox 1
transcription factor known as POU5F1, is expressed in
human embryonic stem cells (hESCs), induced
pluripotent stem cells, early epiblast, and germ cells,
including primordial germ cells [5,6]. This transcription
factor has been implicated in key pluripotency mainte-
nance functions in both early embryogenesis, including
acting as a master regulator in segmentation morphol-
ogy and organogenesis via activation of key downstream
signaling pathways, and activating tissue-specific tran-
scription factors [7]. Interestingly, it has been shown
that precise levels of OCT4 are needed during develop-
ment, as repression leads to loss of pluripotency and
subsequent trophectoderm differentiation and overex-
pression lead to differentiation into primitive endoderm
and mesoderm, respectively [8]. It is clear that OCT4
plays a critical function in human developmental biol-
ogy, and its role has been well defined in that it associ-
ates with other pluripotency factors, SOX2 and NANOG,
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whose mechanism to maintain a pluripotent phenotype
involves upregulation and downregulation of over 4,600
genes through a protein network of these three proteins
[9-11]. Thus, the delivery and stable expression of syn-
thetic OCT4 mRNA and other synthetic mRNAs (synR-
NAs) may have multiple applications for future cell-
based research and therapeutics.
The ability to reprogram easily obtainable human
cells, such as skin cells, back into a pluripotent epige-
netic state provides exciting new possibilities for in vitro
research and patient-specific cellular therapeutics to
regenerate our bodies following injury, disease, and age-
based tissue degeneration [12]. However, the most pro-
mising method for reprogramming human somatic cells
back into a pluripotent state - referred to as induced
pluripotent stem cells - uses viruses to deliver the repro-
gramming factors (OCT4, SOX2 combined with KLF4
and cMYC or with NANOG and LIN28) into human
somatic cells [13,14]. As these viruses randomly inte-
grate into the genome, insertional mutagenesis is an
important safety concern [15-17]. Alternatives to inte-
grating DNA virus-based reprogramming include the
use of episomal plasmids [18] and minicircles [19], pro-
tein-based reprogramming [20], and Sendai virus-based
reprogramming [21]. Both of the episomal DNA-based
reprogramming methodologies, however, still entail
some risk of genomic recombination or insertional
mutagenesis. The recombinant proteins used in protein-
based reprogramming are challenging to generate and
purify in the quantities required, and the RNA-based
Sendai virus requires an extended period of culture in
order to dilute out the viral particles [22]. Perhaps the
most promising current integration-free reprogramming
methodology for future patient-specific cellular thera-
peutics involves the direct transfection of RNAs into
somatic cells (that is, synthetic whole mRNAs [23] or
microRNAs [24] or both). SynRNAs encoding for five of
the reprogramming factors (OCT4, SOX2, KLF4, cMYC,
and LIN28) have been shown to reprogram human
somatic cells back into a pluripotent state [23]. The
most important of these delivered reprogramming fac-
tors is OCT4, as recent research has demonstrated that
OCT4, in combination with certain small molecules, can
itself induce a somatic cell to reprogram to pluripotency
without requiring assistance from the other factors [25].
Here, we examined the expression of synthetic OCT4
mRNA following transfection into adult human skin
cells, investigated whether various small molecules
(B18R, BX795, and BAY11) could significantly increase
synthetic OCT4 mRNA expression, and used transcrip-
tional analysis of OCT4 downstream genes to determine
whether the OCT4 protein maintained its functionality
as a transcription factor.
Materials and methods
Ethics statement
Written approval for human skin biopsy procedures and
human fibroblast derivation, culture, and experimental use
was obtained from the Stanford University Institutional
Review Board, the Stanford University Stem Cell Research
Oversight (SCRO) committee, and written informed con-
sent was obtained from each individual participant. Biopsy
material used in this study was obtained and initially ana-
lyzed at Stanford University, as previously described [26],
and transferred to the University of California at Los
Angeles (UCLA) through a material transfer agreement.
Written approvals for the experiments performed in this
study were obtained from the UCLA Institute Biosafety
Committee and the UCLA SCRO committee.
In vitro culture of primary human skin cells
The human skin-derived (HUF1) primary cell line used in
this study was obtained from a 4-mm adult skin punch
biopsy and cultured as described [26]. Briefly, all human
biopsy-derived cells were cultured in complete DMEM/F-
12 media consisting of Dulbecco’s modified Eagle’s med-
ium nutrient mixture F-12 (DMEM/F-12) supplemented
with 10% fetal bovine serum (FBS), 1 × minimum essen-
tial medium (MEM) non-essential amino acids, 1 × Glu-
tamax, and 100 IU/mL penicillin-streptomycin (all from
Invitrogen Corporation/Gibco, Grand Island, NY, USA)
and maintained at 37°C in a 5% CO2 incubator. Culture
media were changed every two days. Cells were allowed
to expand to 80% to 90% confluency before passaging
with 0.05% trypsin-EDTA (Invitrogen Corporation) and
replating at a 1:3 ratio. A large bank of early-passage
HUF1 cells was cryopreserved in culture media supple-
mented with 10% dimethyl sulphoxide (DMSO) (Sigma-
Aldrich, St. Louis, MO, USA). All research adhered to
National Academy of Sciences guidelines.
In vitro culture of H9 human embryonic stem cells
H9 hESCs (UCLA Broad Stem Cell Research Center-Stem
Cell Core) were cultured in standard ESC conditions as
published [26]. Briefly, hESCs were cultured in medium
consisting of DMEM/F-12 supplemented with 20% knock-
out serum replacement, 1 × Glutamax, 1 × non-essential
amino acids, 100 IU/mL penicillin-streptomycin (all from
Invitrogen Corporation), 1 × b-mercaptoethanol (Millipore
Corporation, Billerica, MA, USA), and 10 ng/mL recombi-
nant human basic fibroblast growth factor (Globalstem,
Rockville, MD, USA) and maintained at 37°C in a 5% CO2
incubator. Media were changed daily.
Cell proliferation analysis
BAY11 and BX795 were purchased from InvivoGen (San
Diego, CA, USA) (catalog code tlrl-b82 and tlrl-bx7).
Awe et al. Stem Cell Research & Therapy 2013, 4:15
http://stemcellres.com/content/4/1/15
Page 2 of 12
Both inhibitors were diluted initially in DMSO to a
stock concentration of 100 mM and stored in aliquots
at −20°C. All further dilutions to working concentrations
were carried out in filter-sterilized Millipore water.
Fresh aliquots were used for each daily transfection.
B18R recombinant protein was purchased from
eBioscience (San Diego, CA, USA), aliquoted, and stored
at −80°C. HUF1 cells were grown as described alone in
complete DMEM/F-12 media. For cell proliferation
experiments, HUF1 cells were plated onto gelatin-coated
six-well plates (Sigma-Aldrich) at a concentration of
50,000 cells (based on a doubling time of 34 hours) and
left to sit for 24 hours to adhere in the presence of
BAY11 or BX795 (as indicated in Figure 1), and this was
considered day 0. Every day at the 24-hour mark, media
were changed with fresh drug and B18R (when applic-
able). On day 5, cells were washed twice with 1 ×
phosphate-buffered saline (PBS) (Invitrogen Corpora-
tion) and cells detached with 1 mL per well of a six-well
plate via 0.05% trypsin-EDTA for 5 minutes at 37°C in a
5% CO2 incubator. Cells were then quenched with 4 mL
of standard fibroblast culture media, centrifuged at 120g
for 5 minutes, and resuspended in 1 mL of culture
media along with Trypan blue stain (Invitrogen Cor-
poration) for cell counting by using a standard hemocyt-
ometer. All cell counts were performed in quadruplicate.
Synthetic mRNA dilutions
For the initial ‘mRNA pooling’ experiments, synRNA of
each of the five reprogramming factors was generated in-
house, aliquoted, and stored at −80°C as previously
described by Warren and colleagues [23]. Briefly, in
accordance with the approach of Warren and colleagues,
a 170:160:420:130:120 stoichiometric ratio corresponding
Figure 1 Immunocytochemical analysis of OCT4 expression. (a-j) Adult human dermal fibroblasts (HUF1) were exposed to different synthetic
mRNA (synRNA) concentrations to stabilize and promote homogenous OCT4 expression. Addition of 1 × or 4.5 × synRNA did not yield
significantly higher OCT4 expression (b,d). Addition of B18R was added to assuage interferon (IFN) signaling, although 1 × and 3 ×
concentrations did not yield significant increases in OCT4 expression (c,e). 4.5 × mRNA at 520 ng and 3 × B18R at 600 ng/mL also did not yield
significant stabilization of OCT4 (f). Small-molecule compounds of BX795 at low (0.001 µM) and high (1 µM) concentrations did yield robust
expression of OCT4 (g and h, respectively). BAY11 at low (0.01 µM) and high (1 µM) concentrations also stabilized OCT4 to an even greater
degree than BX795 (i and j, respectively). Scale bar represents 100 µM. DAPI (4′,6-diamidino-2-phenylindole) staining is represented in blue; OCT4
staining is represented in green. BAY11, BAY 11-7082.
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to ‘KMOSL’ factors (which consisted of KLF4:c-MYC:
OCT4:SOX2:LIN28, respectively) was used for the initial
‘pooling’ experiments. SynRNA stock concentrations for
KMOSL were 1,200, 750, 1,500, 650, and 600 ng/µL,
respectively, and were all diluted to 100 ng/µL stocks
with Tris-EDTA pH 7.0. To pool these together with the
same stoichiometric ratios used by Warren and collea-
gues, 121.4, 114.3, 300, 92.9, and 64.3 µL, respectively,
were added together on ice and under sterile conditions,
mixed, and immediately placed into 12-µL aliquots for
storage at −80°C. Thus, each vial had a cocktail of the
five factors at 100 ng/µL to yield 1,200 ng total per ali-
quot of synRNA, and the synRNA cocktails - except for
OCT4, which was present at a 3 × molar concentration -
were formulated to yield equal molarity. For the later
OCT4 mRNA experiments, only OCT4 synRNA, obtained
from a commercial vendor (Stemgent, San Diego, CA,
USA), was used.
Synthetic mRNA transfection
All work was carried out in strict RNAse-free condi-
tions. SynRNA was thawed on ice and quickly diluted
before degradation. SynRNA was diluted 5 × by using
Opti-MEM basal media (Invitrogen Corporation) with
12 µL of synRNA at 100 ng/µL placed into 48 µL of
Opti-MEM. RNAiMAX was used at 5 µL per microgram
of RNA - 1.2 µg of total synRNA and thus 6 µL of
RNAiMAX - and was diluted 10 × by diluting 6 µL of
RNAiMAX into 54 µL of Opti-MEM. Each dilution was
separate, and the tube was mixed. The two dilutions
were pooled, mixed, and incubated at room temperature
for 15 minutes. This mixture was added directly into
fibroblast culture media without antibiotics, as required
by protocol. Final culture volumes in each well were 500
µL. The cells were left to incubate with the synRNA for
4 hours, after which the media were replaced with fresh
BAY11 or BX795 along with B18R all in standard fibro-
blast media. For the OCT4 mRNA single-factor assay,
daily transfections were carried out as above onto
25,000 HUF1 cells plated into a 24-well plate by using
synthetic OCT4 mRNA (Stemgent) over the course of 5
days, with or without the addition of BAY11. B18R was
not included during the single-factor transfections.
Immunocytochemistry
Cultured cells were fixed in 4% paraformaldehyde/1 ×
PBS for 15 minutes, washed twice with 1 × PBS supple-
mented with 100 mM glycine for 5 minutes, and incu-
bated with permeabilization buffer consisting of 0.1%
Triton X-100 (Sigma-Aldrich) in 1 × PBS for 30 minutes
at room temperature. Blocking was performed with 4%
goat serum in Blocker Casein in PBS (Thermo Scientific,
Rockford, IL, USA) for 60 minutes at room temperature.
Then OCT4 (C-10) mouse anti-human monoclonal
IgG2b 1:200 (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA, USA; catalog code sc-5279) was added to 4% goat
serum in Casein-PBS and incubated overnight at 4°C.
The next day, cells were washed three times with 1 ×
PBS before Alexa Fluor 488 goat anti-mouse IgG 1:200
(Invitrogen Corporation) was added to 4% goat serum in
Casein-PBS and incubated for 1 hour at room tempera-
ture. The cells were rinsed and stained with SlowFade
Gold antifade reagent with 4′,6-diamidino-2-phenylin-
dole (DAPI) (Invitrogen Corporation) for 10 minutes,
followed by two 1 × PBS washes. Cultures were visua-
lized with an AxioCam MR Monocolor Camera by
using AxioVision Digital Image Processing Software
(Axio Observer Inverted Microscope; Carl Zeiss, Jena,
Germany). Three images per well were used for lumin-
osity cell counts evaluated with Adobe Photoshop
(Adobe Systems, Mountain View, CA, USA). In each
replicate, 10 cells located in the top left frame of the
picture were characterized with the luminosity tool in
Photoshop.
OCT4 quantification
The OCT4 stabilization assay was carried out via a 10 ×
dilution of the 100 ng/µL synRNA stock across 10 wells
for a total of 120 ng per well in a 24-well plate. In total,
10,000 cells per well were plated, and all synRNA dilu-
tions were carried out as stated above. Cells were cul-
tured in standard fibroblast media, without antibiotics,
overnight. The day after the initial plating, each combi-
nation of BAY11 or BX795, with or without B18R, was
diluted directly into cell culture medium for 24 hours to
precondition the medium. SynRNA was then transfected
in every 24 hours with fresh replacement of media and
drug for 5 days. OCT4 was then quantified via immuno-
cytochemical analysis and analyzed as previously
mentioned via immunocytochemical and luminosity
measurements in Photoshop.
Global transcriptional meta-analysis
In total, 25,000 passage 5 HUF cells were plated into
individual wells in a 24-well plate in standard DMEM/
FBS media without antibiotics. Twelve hours later, the
cells were incubated with 1 µM BAY11 + 200 ng/mL
B18R over two wells, whereas the other two wells
received just B18R at 200 ng/mL final concentration.
The final volume was 500 µL in each well. After 24
hours of incubation, the cells were transfected with the
modified synRNA as detailed above. This was carried
out every day for 3 days, and after the last incubation
period of 24 hours, the cells were harvested for mRNA
by using a Roche High Pure RNA Isolation Kit in accor-
dance with the instructions of the manufacturer (Roche,
Indianapolis, IN, USA). hESCs and control fibroblasts
were harvested in the same manner. Microarray analysis
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was carried out as published [27]. Briefly, total RNA was
used for an Affymetrix Differential Gene Expression
Assay Human Genome U133 Plus 2.0 Array (Genoseq
UCLA) for global transcriptional analysis by using stan-
dard Affymetrix protocols (Affymetrix GeneChip
Expression Analysis Technical Manual, rev. 3. 2001).
Uploading and cluster analysis of the CEL files between
replicate samples were carried out through GeneSifter
(VizX Labs, Seattle, WA, USA[28]) by using the
Advanced Upload Method and were normalized by
using the Affymetrix Microarray Analysis Suite (MAS)
5.0 algorithm. The following CEL files were used for
this analysis: HUF1 cells transfected with synRNA but
not treated with BAY11 (GSM994323 and GSM994324),
HUF1 cells transfected with synRNA and treated with
BAY11 (GSM994325 and GSM994326), HUF1 cells not
transfected with synRNA and not treated with BAY11
(GSM994327 and GSM994328)
and H9 human embryonic stem cells (GSM994321 and
GSM994322). Data from control HUF cells were used as
a baseline control to compare the replicates of HUF cells
with or without BAY11 and hESCs. All experimental
details for the microarray analysis, including all original
CEL files, have been made publically available at the
Gene Expression Omnibus [29] GSE40444.
Quantitative polymerase chain reaction analysis
Total mRNA that was harvested from the global tran-
scriptional meta-analysis was also used in reverse tran-
scription-polymerase chain reaction (RT-PCR) for
quantitative PCR analysis. The RNA yield and quality
were determined by using the GE NanoVue Spectro-
photometer (GE Healthcare Life Sciences, Piscataway,
NJ, USA). For hESCs and for all HUF lines, 1 µg and
180 ng of RNA, respectively, were reverse-transcribed by
using the Transcriptor First Strand cDNA Synthesis Kit
(Roche) and anchored-oligo(dT)18 and random hexamer
primers. Quantitative RT-PCR (QPCR) relative expres-
sion experiments used a LightCycler 480 Real-Time
PCR System (Roche), and data were further analyzed
with LightCycler 480 Software release 1.5.0. Primers and
probes were designed and ordered from Roche’s Univer-
sal ProbeLibrary. Primers for the genes are listed as fol-
lows: Homo sapiens secreted phosphoprotein 1 (SPP1),
transcript variant 2, mRNA (NM_000582.2) forward pri-
mer: cgcagacctgacatccagt, reverse primer: ggctgtcccaat-
cagaagg, probe #61; Homo sapiens solute carrier family
16, member 9 (monocarboxylic acid transporter 9)
(SLC16A9), mRNA, (NM_194298.2), forward primer:
gatgcctttggtgaaggaaa, reverse primer: cacagagactgcaga-
caggact, probe #64; Homo sapiens growth arrest and
DNA-damage-inducible, gamma (GADD45G), mRNA,
(NM_006705.3), forward primer: cagccaaagtcttgaacgtg,
reverse primer: cctggatcagcgtaaaatgg, probe #71;
DUSP4-001 dual-specificity protein phosphatase 4
(ENST00000240100.2), forward primer: tgcatcccagtggaa-
gataac, reverse primer: gcagtccttcacggcat, probe #17;
Homo sapiens hypoxanthine phosphoribosyltransferase
1 (HPRT1), mRNA, (NM_000194.2), forward primer:
tgaccttgatttattttgcatacc, reverse primer: cgagcaagacgtt-
cagtcct, probe #73; GAPDH-001 glyceraldehyde-3-phos-
phate dehydrogenase (ENST00000229239.5), forward
primer: gctctctgctcctcctgttc, reverse primer: acgac-
caaatccgttgactc, probe #60. cDNA (5 ng) that was
reverse-transcribed in the RT-PCR per sample was used
in a 20-µL reaction that consisted of 10 µM UPL probe,
2 × LightCycler 480 Probes Master, and 20 µM forward
and reverse primers. Duplicate experimental samples
were paired by using the all-to-mean pairing rule with
two housekeeping genes run in duplicate for advanced
relative quantification.
Statistical analysis
Results are presented as mean ± standard deviation. The
statistical significance of differences for cell proliferation
analysis, immunocytochemical luminosity-based quanti-
fication, and QPCR results were evaluated by using Sta-
tistical Package for the Social Sciences (SPSS) 20 (IBM
Corporation, Chicago, IL, USA). Analysis of variance, t
test for independent samples, and Mann-Whitney U test
were considered statistically significant at a P value of
less than 0.05.
Results
Immunocytochemical detection of OCT4 demonstrating
robust stabilization
In our initial attempts to repeat the reprogramming
methodology of Warren and colleagues [23] for trans-
fecting synthetic (syn) OCT4 mRNA into human adult
fibroblasts, we observed significant degradation (defined
here by low-level and heterogeneous OCT4 expression)
of the OCT4 synRNA. Interestingly, this degradation
appeared to be specific to OCT4 and did not affect
SOX2, KL4, cMYC, and LIN28 (data not shown), but the
reasons for this are not yet clear. No detectable OCT4
protein was observed in the untransfected human adult
fibroblasts (HUF1) (Figure 1a). After transfection of 120
ng of synRNA (as reported by Warren and colleagues
[23]), we saw broad heterogeneity and very low expres-
sion of OCT4 upon immunocytochemical analysis (Fig-
ure 1b). Secondly, addition of Vaccinia virus decoy
receptor for type I interferons (IFNs), identified as
B18R, resulted in no statistically significant increase in
OCT4 expression (Figure 1c), and no significant increase
was observed following the use of higher amounts of
synRNA (Figure 1d), B18R (Figure 1e), or both (Figure
1f). These results demonstrate that increasing synRNA
concentration and mitigating IFN signaling via B18R are
Awe et al. Stem Cell Research & Therapy 2013, 4:15
http://stemcellres.com/content/4/1/15
Page 5 of 12
not sufficient to permit robust OCT4 expression from
synRNA.Next, we analyzed the immune response path-
ways to identify alternative potential small-molecule
candidates that could potentially block the intra-cellular
immune response pathway and thus stabilize OCT4
expression from synRNA (Figure 2a). The degradation
of synthetic single-stranded RNA (ssRNA) is elicited
through two distinct pathways (Figure 2a). First, interac-
tion between pathogen-associated molecular patterns,
including ssRNA [30], leads to activation of the mito-
gen-activated protein kinases (MAPKs) and the IB
kinase (IKKa and IKKb), which subsequently turn on
nuclear factor-kappa-B (NF-B), via phosphorylating
IBa [31]. The second pathway uses another subset of
pattern recognition receptors - endosomal Toll-like
receptors [32], melanoma differentiation-associated gene
5 (MDA-5), and retinoic acid-inducible gene I (RIG-1) -
that activate a distinct pathway which requires IKK-
related kinases, IKKε, and TANK-binding kinase 1
(TBK1) and which also leads to activation of NF-B and
NF-B-based gene transcription [31]. Both pathways
recognize foreign RNA, and subsequent NF-B-based
activation of IFN regulatory factor (IRF) leads to type I
IFN production [33-35]. Thus, inhibitor B (IB) pro-
teins, normally sequestering NF-B in the cytoplasm,
must undergo phosphorylation via IB kinase a (IKK)
and subsequent rapid proteasome degradation, allowing
NF-B transcriptionally based regulated IFN production
[36]. BAY11 inhibits IBa phosphorylation (specifically,
IRF7 production) [37,38], whereas BX795 inhibits TBK1
and IKKε. Both BAY11 and BX795 ultimately may inhi-
bit many degradation-associated cytokines, RNAse L,
and chemokines [31] (Figure 2a). Warren and colleagues
found that use of modified ribonucleoside bases and a
phosphatase treatment to reduce the signaling through
RIG-1, coupled with an IFN inhibitor B18R, led to sig-
nificantly reduced innate immune responses [39],
although it did not completely eliminate this synRNA
degradation in our experiments. We then asked whether
two other candidate small molecules (BX795 and
BAY11) might efficiently block the intracellular immune
response to synthetic RNA and stabilize OCT4 expres-
sion (Figure 2a). When combined with 120 ng of total
synRNA, BX795 at the low concentration (0.001 µM)
induced broad stabilization and homogenous expression
of OCT4 (Figure 1g). We then investigated whether
increasing the concentration of BX795 to 1 µM would
increase OCT4 expression. As shown in Figure 1h, a
greater number of cells did express OCT4 but at a level
comparable to that of BX795 at 0.001 µM (Figure 1g).
Next, we tested a similar compound, BAY11, at a low
concentration (0.01 µM) and obtained robust OCT4 sta-
bilization and more uniform expression (Figure 1i). This
was followed by one last condition tested with BAY11 at
a high concentration (1 µM), and we found dramatically
increased OCT4 expression (Figure 1j). In comparison,
the original conditions of just synRNA and B18R yielded
low and very heterogeneous expression of OCT4 (Figure
1b,c). To further investigate the reproducibility of this
phenomenon, we used OCT4 synRNA alone, bought
from an independent commercial manufacturer (Stem-
gent), and were able to duplicate the response seen in
Figure 1, even in the absence of B18R (Figure 3a-c).
This indicates that BAY11, and not the modified nucleo-
bases or B18R, is the main contributing factor that is
allowing the mRNA stabilization. In an effort to investi-
gate whether the NF-B-based innate immune response
pathway is involved in this OCT4 stabilization phenom-
enon (as we hypothesized), we performed an assay with-
out transfection of B18R or multiple pooled mRNAs.
Not only did we still observe the stabilization of OCT4
expression but we also observed, through quantitative
PCR, a statistically significant decrease in NF-B expres-
sion when in the presence of BAY11 after daily transfec-
tion of synthetic OCT4 mRNA alone (Figure 2b). This
correlative evidence suggests that the reproducible and
robust increase in OCT4 mRNA expression we have
observed is due, at least in part, to the inhibition of the
NF-B-based innate immune response pathway.
Quantitation of immunocytochemistry and cell
proliferation analysis
Luminosity-based measurements were used to quantify
which conditions yielded significantly increased relative
expression of OCT4. Fluorescent imaging demonstrated
that BAY11 at 1 µM yielded the highest statistically sig-
nificant relative expression of OCT4, followed closely by
BAY11 at 0.01 µM (Figure 4a). There were no differ-
ences between the expression levels of OCT4 induced
by BX795, and both were lower than the BAY11 con-
centrations (Figure 4a). We then conducted a cell prolif-
eration assay on the HUF cells and found that both
concentrations of BX795 and BAY11 at 1 µM have sig-
nificant cell proliferative defects when compared with
controls. However, BAY11 at 0.01 µM had the best
compromise between robust OCT4 expression and no
statistically significant reduction in cell proliferation
compared with controls (Figure 4b). According to these
findings, BAY11 used at 0.01 µM yielded optimal OCT4
expression without cell proliferative defects.
Global transcriptional meta-analysis and quantitative
polymerase chain reaction
Next, we investigated whether global transcriptional
meta-analysis could ascertain any early easily activated
downstream transcriptional targets of OCT4 that may
also be upregulated because of OCT4 stabilization in the
presence of BAY11. Pairwise analysis of control and
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Figure 2 Overview of molecular signaling pathway and quantitative real-time polymerase chain reaction analysis of nuclear factor-
kappa-B (NF-B). (a) Dotted line represents the molecular pathway that BX795 inhibits, specifically at IKKε. The pathway with non-dotted lines
represents the additional pathways that BAY11 inhibits, including the IKKb and IRF7 pathways. (b) Relative NF-B levels with and without BAY11.
Overall levels decrease in the presence of BAY11, contributing to the increase in OCT4 expression previously seen. Asterisks indicate statistically
significant changes in expression where P value was less than 0.05. BAY11, BAY 11-7082; IFNAR, interferon-a/b receptor; IKK, IB kinase; IRAK1,
interleukin-1R-associated kinase 1; IRF, interferon regulatory factor; ; ISRE, interferon stimulated response element; MDA5, melanoma
differentiation-associated gene 5; MYD88, myeloid differentiation primary-response gene 88; RIG-I, retinoic acid-inducible gene I; STAT1/2, signal
transducer and activator of transcription 1/2; TLR7/8; TRAF6, tumor necrosis factor receptor-associated factor 6.
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BAY11-treated fibroblasts revealed a number of probe
sets upregulated (P <0.05, fold change >3). The differen-
tially upregulated genes (when compared with our base-
line HUF cells), in the presence of BAY11, were then
cross-referenced with these genes in the ESC microarray.
Further comparison of the downstream targets of OCT4
was carried out with previously reported results from the
chromatin immunoprecipitation paired-end ditags metho-
dology, global expression profiling, and chromatin-immu-
noprecipitation analysis [9-11]. From these data, four
putative gene targets were found to be consistently upre-
gulated: SPP1, DUSP4, GADD45G, and SLC16A9 (Figure
5a). These putative genes were confirmed with QPCR;
however, the differential levels of gene expression
observed via QPCR were, for unknown reasons, generally
lower than those observed for microarray analysis. We
demonstrated that, in the presence of BAY11, the expres-
sion of these four OCT4 early target genes was signifi-
cantly increased relative to untreated HUF cells (Figure
5b). Interestingly, in the presence of BAY11, HUF cell
expression of these four genes more similarly matched
expression levels of hESCs, suggesting that BAY11 could
be useful in reprogramming by upregulating key pluripo-
tency-associated genes. Additionally, while SPP1, DUSP4,
and GADD45G were previously found to be bound and
regulated by OCT4 [9-11], we found a putative novel
OCT4 target gene, SLC16A9, that has been previously
shown through microarray analysis to also be upregulated
in ESCs. Thus, through microarray analysis and QPCR,
we detected and confirmed four early gene targets that
are upregulated in the presence of BAY11, indicative of
functional OCT4 expression.
Figure 3 Immunocytochemical analysis of OCT4 expression with OCT4 mRNA alone. (a-c) HUF1 cells were exposed to 0 × and 1 ×
synthetic OCT4 mRNA without B18R and in the presence or absence of BAY11. The addition of BAY11 was noted to again stabilize and allow
homogenous expression of OCT4 without the presence of B18R or any other mRNAs in culture. Scale bar represents 100 µM. DAPI (4′,6-
diamidino-2-phenylindole) staining is represented in blue; OCT4 staining is represented in green. BAY11, BAY 11-7082; synRNA, synthetic mRNA.
Figure 4 Relative OCT4 expression levels and relative proliferation rate. (a) Quantitative analysis of immunocytochemically detected OCT4
expression. (b) Proliferation analysis following exposure to small molecules. Asterisks indicate statistically significant increases or decreases over
controls where P value was less than 0.05. BAY11, BAY 11-7082; synRNA, synthetic mRNA.
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Discussion
In this study, we provide the first significant and reprodu-
cible evidence, collected over four independent experi-
ments, in support of the hypothesis that BAY11 can
significantly increase the expression of OCT4 in human
adult dermal fibroblasts from transfected synRNA with-
out negatively impacting cell proliferation. We demon-
strated that this response involves NF-B-based innate
immune responses and is independent of the modified
nucleobases and addition of B18R. Also, we were able to
reproduce the robust expression of OCT4 by using
single-factor mRNA synthesized from an independent
company (Stemgent) rather than our original source of
synRNA (generated in-house). Importantly, OCT4 can
significantly upregulate its putative early target down-
stream genes, including SPP1, DUSP4, and GADD45G.
For example, dual-specificity phosphatase 4 (DUSP4)
plays a role in cellular proliferation and differentiation via
phosphatase activity in the MAPK pathways, and previous
studies reported that deletion of this gene causes a signif-
icant decrease in the cell proliferation rate [40]. Similarly,
c-MYC has many downstream targets that enhance cell
Figure 5 Microarray analysis and quantitative real-time polymerase chain reaction (QPCR) of genes upregulated by BAY11. (a)
Microarray data show four putative gene targets that were identified by over 3 × fold changes in human fibroblast (HUF) cells treated with
BAY11compared with untreated HUF cells over the course of 3 days of daily synthetic mRNA transfections. (b) QPCR analysis confirmed
microarray results for the four genes and demonstrated that relative expression of the four genes becomes more similar to human embryonic
stem cell (hESC) expression in the presence of BAY11. Asterisks indicate statistically significant increases over control cells not receiving BAY11
where P value was less than 0.05. BAY11, BAY 11-7082; DUSP4, dual-specificity phosphatase 4; SLC16A9, solute carrier family 16, member 9.
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proliferation [13], and DUSP4 may have similar functions
in reprogramming to increase cell proliferation. We also
used global transcriptional analysis to identify a novel
OCT4 target gene (SLC16A9) and demonstrated that
SLC16A9 was significantly upregulated following BAY11-
based treatment of adult human skin cells transfected
with synthetic OCT4 mRNA. SLC16A9 (or solute carrier
family 16, member 9) is a monocarboxylic acid transpor-
ter, which is interesting as highly glycolytic cells com-
monly express monocarboxylate transporters [41].
Interestingly, SLC16A9 is part of the monocarboxylate
transporter family of H+/lactate symporters capable of
bidirectional transport of lactic acid across the plasma
membrane [42]. This is an important finding as ESCs
have been found to be primarily glycolytic and have very
few mitochondria [43]. Thus, ESCs, and most malignant
cancers, express this glycolytic phenotype, even in the
presence of oxygen, an effect known as the ‘Warburg
effect’, and must efflux lactate to prevent toxic intracellu-
lar buildup of lactate [44]. Therefore, upregulation of
SLC16A9 could be another avenue by which to increase
reprogramming efficiency not only in mRNA-based
reprogramming but also in other reprogramming
methodologies.
It is interesting to note that, out of the various repro-
gramming factors we analyzed (OCT4, SOX2, KLF4,
cMYC, and LIN28), only OCT4 triggered an intracellular
immune response that resulted in very low heteroge-
neous expression. Whether OCT4 more closely resem-
bles an evolutionarily recognized single-stranded virus
that human somatic cells have evolved defense mechan-
isms to is an interesting hypothesis but as of yet is
unproven. Also, exactly how human fibroblasts recog-
nize and degrade transfected human OCT4 RNA and
whether the polyA or 3′ untranslated region sequences
play a role are unclear. We propose that human cells
use the same intracellular immune response pathways
that degrade viral single-stranded mRNA to degrade sin-
gle-stranded OCT4 mRNA. The difference in recogni-
tion and degradation between synthetic OCT4 and
endogenous OCT4 may reside in the relatively long half-
life of viral mRNA and synRNA compared with the rela-
tively short half-life of endogenous OCT4 mRNA (which
is nevertheless continuously transcribed when
expressed). This is an interesting area for future study.
It should also be noted that, while the immunocyto-
chemical assays we have used in this study do not dis-
tinguish between endogenous and exogenous OCT4
protein, we do not consider that this is a significant
concern or changes the conclusions of our paper, as no
detectable OCT4 protein was observed via the immuno-
cytochemical assay in the human dermal fibroblasts
without OCT4 synRNA transfection. It is also interesting
to note that, for unknown reasons, the RT-PCR primers
we have previously used to detect endogenous OCT4
mRNA did not work with synthetic OCT4 mRNA.
Therefore, we focused our quantitative analysis in this
study on the increased amount of OCT4 protein gener-
ated in the synRNA transfected cells and the significant
upregulation of genes downstream of OCT4. In regard
to the detection of only four OCT4 putative targets, it is
unclear to us why a larger number of OCT4 down-
stream genes did not get upregulated, although we pro-
pose that the four putative OCT4 targets we identified
in this study may potentially represent some of the ear-
liest or easiest genes to upregulate (or both), hence their
detection in our microarray and QPCR assays, while
other OCT4 targets may require additional factors or
time (or both) to express to detectable levels. To date,
we have observed that BAY11 can significantly and
reproducibly stabilize OCT4 over a 3-day and 5-day cul-
ture. It will be interesting to observe whether BAY11
can maintain this stabilized OCT4 expression over
longer periods of time without inducing any negative or
toxic effects (or both) on the cells. This long-term
synRNA stabilization is critical toward almost all future
applications of BAY11.
This research represents the first step toward using
small molecules to augment the expression of various
synRNAs in adult human somatic cells. At present, the
molecular mechanism involved in the increased pre-
sence of OCT4 protein is not clear and may involve
increased mRNA stability, translation, or improved
transfection efficiency. Given that BAY11 has been
found to suppress IRF7 production [37,38], tempering
the innate immune response-mediated decay of exogen-
ous mRNA is a plausible mechanism and likely involves
increased mRNA stability of the transfected OCT4
mRNA. This is an interesting area for future study. In
addition, our results indicate that BAY11 may be an
important adjuvant to augment reprogramming to pluri-
potency [23], differentiation to endoderm [8], and/or
expression of other potentially useful synRNA-derived
factors. One of the most promising aspects of this study
is the potential that BAY11 may be useful in stabilizing
synthetic OCT4 mRNA to facilitate the generation of
patient-specific induced pluripotent stem cells. This is
especially relevant given that past findings have detailed
that perhaps one of the biggest roadblocks during repro-
gramming via frequent mRNA transfections is an innate
immune response [45]. Therefore, for the first time, we
show that a small molecule, BAY11, can mitigate this
innate immune response and partially prevent degrada-
tion of transfected synRNA.
Conclusions
We conclude that BAY 11-7082 (BAY11) can signifi-
cantly increase the expression of OCT4 following
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transfection of synRNA into adult human skin cells.
This small molecule-based stabilization of synRNA
expression may have multiple applications for future
cell-based research and therapeutics.
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